WEARABLE
NEURAXPHARM AND MJN-NEURO PROVIDE AN EARLY WARNING OF EPILEPTIC SEIZURES
Neuraxpharm , a leading European specialty pharmaceutical company focused on the central nervous system ( CNS ), and mjn-neuro , a start-up that designs , manufactures and markets medical devices , have announced the signing of a commercialisation agreement for mjn-SERAS , a wearable medical device that aims to predict the risk of having an epileptic seizure .
Dr . Jörg-Thomas Dierks , CEO of Neuraxpharm , said : " The agreement to commercialise mjn-SERAS is an important step in our strategy to offer end-to-end solutions for patients with epilepsy . There is a huge unmet medical need for new and innovative solutions to help patients suffering from epilepsy . By entering the digital health market , Neuraxpharm can provide further assistance and tap this unmet potential . We will continue expanding our offering to provide new digital health solutions to patients suffering from epilepsy and other CNS disorders across the world ."
With this agreement , Neuraxpharm increases its end-toend offering for patients with epilepsy and enters the beyond-the-pill solutions market . This is a significant step for the company on its path to entering the digital health and wearable medical devices markets . With a growing demand from patients seeking different solutions for unmet needs and for healthcare systems to simplify the go-tomarket pathways to make these solutions attainable for everyone , digital health is a critical component of care in CNS with significant potential .
The agreement with mjn-neuro covers all EU member states as well as the UK , Norway , Iceland , Liechtenstein and Switzerland . Since 2020 , mjn-SERAS has been receiving funding from the European Institute of Technology Health ( EIT Health ), a body of the European Union , during the development of the project thanks to the Bridgehead programme and Start-up Amplifier . In 2018 , the project was backed by the EU funding programme Horizon 2020 , initiated by the European Commission and it also has the participation of a consortium of companies and healthcare professionals .
" We are at a great point in the evolution of mjn-neuro ," added David Blánquez , CEO and Co-Founder of mjn-neuro .
" The agreement signed with Neuraxpharm is a major milestone for our strategy and scalability in the epilepsy market , a market that offers great potential . We have a lot in common with Neuraxpharm : we ' re both committed to innovation and digital health as a way to improve the quality of life of people with epilepsy . Therefore , we are confident that together we will be able to reach exciting new goals and objectives in the coming years ." �
www . intelligenthealth . tech 55